We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Cheap, Non-Invasive Blood Test Predicts Alzheimer's Risk 20 Years Ahead of Symptoms

By LabMedica International staff writers
Posted on 20 Sep 2023
Print article
Image: A simple test can help predict risk of Alzheimer\'s disease 20 years in advance (Photo courtesy of 123RF)
Image: A simple test can help predict risk of Alzheimer\'s disease 20 years in advance (Photo courtesy of 123RF)

At present, Alzheimer's disease is usually identified through signs of cognitive decline, a stage where the brain has already sustained significant damage. Conventional methods for early detection are not only costly but also invasive, typically involving procedures like lumbar punctures that are both physically and emotionally strenuous for the patient. Now, a simple, cheap, and non-invasive blood test may be capable of assessing the likelihood of someone developing Alzheimer's up to two decades before any symptoms appear.

A team of physicists from The Australian National University (ANU, Canberra, Australia) has combined nanotechnology and artificial intelligence (AI) to analyze proteins in the blood for early indicators of neurodegeneration, or specific "biomarkers" signaling the onset of Alzheimer's. Proteins are essentially the foundation of life, containing unique genetic blueprints for each person that offer valuable insights into our health, including the degeneration of brain cells. Locating these proteins with early neurodegeneration markers is like finding a needle in a haystack, according to the researchers.

To tackle this, physicists at ANU have developed an ultra-thin silicon chip embedded with "nanopores," or tiny nanometer-sized holes, that single out proteins for analysis with the aid of a sophisticated AI algorithm. A tiny blood sample is placed on the silicon chip, which is then put into a handheld device roughly the size of a smartphone. This device employs the AI algorithm to sift through the blood sample for protein markers indicative of early-stage Alzheimer's. Notably, the researchers say that the algorithm has the potential to be adapted to screen for various neurological conditions concurrently, such as Parkinson's disease, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). The ANU scientists anticipate that this screening method could become accessible within the next five years. The study has been published in the journal Small Methods.

"Blood is a complex fluid that contains more than 10,000 different biomolecules. By employing advanced filtration techniques and harnessing our nanopore platform, combined with our intelligent machine learning algorithms, we may be able to identify even the most elusive proteins," said ANU Ph.D. researcher Shankar Dutt.

Related Links:
ANU 

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.